(Q64163825)

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Survival after Initial Diagnosis of Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Translational research on the way to effective therapy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Nerve growth factor treatment in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Survival following a diagnosis of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Strategies for disease modification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Involvement of Notch signaling in hippocampal synaptic plasticity

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

The effects of a novel NSAID on chronic neuroinflammation are age dependent.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Alzheimer's disease care: costs and potential savings.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Emerging prospects for the disease-modifying treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Survival among patients with dementia from a large multi-ethnic population

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Frontotemporal dementia progresses to death faster than Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

https://api.crossref.org/works/10.1017%2FS1092852900020629

1 reference

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Alzheimer disease therapy: can the amyloid cascade be halted?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Alzheimer Disease in the US Population

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Immunotherapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Coxibs and Alzheimer's disease: should they stay or should they go?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Pharmacotherapeutic approaches to the prevention of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Risk factors for vascular dementia and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Novel therapeutic strategies for Alzheimer's disease based on the forgotten reproductive hormones

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

The role of biomarkers in clinical trials for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

An editorial update: Annus horribilis for vitamin E

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021

Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900020629

7 January 2021